Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) EBT Margin (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed EBT Margin for 4 consecutive years, with 529.43% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 106729.0% to 529.43% in Q3 2025 year-over-year; TTM through Sep 2025 was 64.22%, a 94169.0% increase, with the full-year FY2024 number at 96.02%, up 22211.0% from a year prior.
  • EBT Margin was 529.43% for Q3 2025 at 60 Degrees Pharmaceuticals, up from 1718.63% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 8153.48% in Q3 2023 to a low of 15126.2% in Q1 2023.
  • A 4-year average of 1015.58% and a median of 529.43% in 2025 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 1553126bps in 2024; the steepest drop was -975020bps in 2024.
  • 60 Degrees Pharmaceuticals' EBT Margin stood at 4492.13% in 2022, then crashed by -83bps to 764.4% in 2023, then soared by 188bps to 2202.75% in 2024, then plummeted by -124bps to 529.43% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's EBT Margin are 529.43% (Q3 2025), 1718.63% (Q2 2025), and 1147.79% (Q1 2025).